Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Margot Chima"'
Autor:
Margot Chima, Gary Beck Dallaghan
Publikováno v:
Medical Education Online, Vol 21, Iss 0, Pp 1-5 (2016)
Background: Objective structured clinical examinations (OSCEs) have been used to assess the clinical competence and interpersonal skills of healthcare professional students for decades. However, the relationship between preclinical (second year or M2
Externí odkaz:
https://doaj.org/article/c7a0c9aea634498083d99e20c4c44250
Autor:
Khek-Chian Tham, Rachel Lefferdink, Kaibo Duan, Seong Soo Lim, X.F. Colin C. Wong, Erin Ibler, Benedict Wu, Hajar Abu-Zayed, Stephanie M. Rangel, Ester Del Duca, Mashkura Chowdhury, Margot Chima, Hee Jee Kim, Bernett Lee, Emma Guttman-Yassky, Amy S. Paller, John E. A. Common
Publikováno v:
British Journal of Dermatology. 187:557-570
Background The ichthyoses are rare genetic keratinizing disorders that share the characteristics of an impaired epidermal barrier and increased risk of microbial infections. Although ichthyotic diseases share a T helper (Th) 17 cell immune signature,
Autor:
Rachel Lefferdink, Stephanie M. Rangel, Margot Chima, Erin Ibler, Ana B. Pavel, HeeJin Kim, Benedict Wu, Hajar Abu-Zayed, Jianni Wu, Kathryn Jackson, Giselle Singer, Keith A. Choate, Emma Guttman-Yassky, Amy S. Paller
Publikováno v:
Archives of Dermatological Research. 315:305-315
Treatment of congenital ichthyoses primarily focuses on reversing skin scaling and is not pathogenesis based. Recent studies showed Th17 immune skewing, as in psoriasis, across the spectrum of ichthyosis, suggesting that targeting this pathway might
Autor:
Hee Jin Kim, Grace Kimmel, Jennifer Bares, Soo Jung Kim, Giselle Singer, Alex Yaroshinsky, Margot Chima, Mark Lebwohl, Jerry Bagel
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:524-529
Background: Brodalumab is an interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe plaque psoriasis. Our prior publication reported significant disease improvement with brodalumab in psoriasis patients who had previous
Autor:
Mark Lebwohl, Emma Guttman-Yassky, Giselle Singer, Jason E. Hawkes, Yael Renert-Yuval, Jennifer Bares, Margot Chima, Patricia Gilleaudeau, Sandra Garcet, Ana B. Pavel, James G. Krueger, Mary Sullivan-Whalen
Publikováno v:
Allergy
BACKGROUND Treatments for alopecia areata (AA) patients with extensive scalp hair loss are limited, and recent evidence supports a role for type 2 T-cell (Th2)-immune response in AA. Dupilumab, a monoclonal antibody inhibiting Th2 signaling, approved
Autor:
Randall Li, Giselle Singer, John K Nia, Ana B. Pavel, Peter W Hashim, Hee Jin Kim, Emma Guttman-Yassky, Xiangyu Peng, Danielle Baum, Yasaman Mansouri, Anjali S. Vekaria, Hui Xu, Grace Kimmel, Yeriel Estrada, Margot Chima, Benjamin Ungar, Mark Taliercio
Publikováno v:
Journal of Allergy and Clinical Immunology. 147:394-397
Autor:
Yael Renert-Yuval, Joel Correa da Rosa, Sandra Garcet, Ana B. Pavel, Jennifer Bares, Margot Chima, Jason E. Hawkes, Patricia Gilleaudeau, Mary Sullivan-Whalen, Giselle K. Singer, James G. Krueger, Emma Guttman-Yassky
Publikováno v:
The British journal of dermatologyReferences. 187(4)
Summary Background Although alopecia areata (AA) greatly impacts patients’ quality of life (QoL), there is no adequate validation of AA-targeted QoL surveys in clinical trials, hindering sufficient representation of patient-reported outcomes. Objec
Publikováno v:
Journal of drugs in dermatology : JDD. 21(3)
Perifolliculitis capitis abscedens et suffodiens or dissecting cellulitis (DC) is a rare and chronic disease with a predilection for the occipital, vertex, and parietal scalp. DC is characterized by multinodular lesions with purulent drainage and sin
Publikováno v:
Journal of Drugs in Dermatology. 19:1050-1055
Laser resurfacing has progressed since the 1980s to treat a variety of medical and aesthetic indications with ever-evolving safety parameters. While laser technology has evolved to provide a more favorable safety profile and decrease wound healing ti
Autor:
Matthew Gagliotti, Tinley Chen, John K Nia, Christopher J. Yao, Margot Chima, Jordan Genece, Peter W Hashim, Grace Kimmel, H. Kim, Mark Lebwohl, Giselle Singer, Danielle Baum, Jennifer Bares
Publikováno v:
Journal of the American Academy of Dermatology. 82:360-365
Background Psoriasis of the intertriginous, anogenital, and facial regions remains a therapeutic challenge, with current algorithms lacking a topical agent that exhibits both high efficacy and minimal side effects. Objective To assess the safety and